Cargando…

Topical Rapamycin Therapy to Alleviate the Cutaneous Manifestations of Tuberous Sclerosis Complex: A Double-Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of Topically Applied Rapamycin

BACKGROUND AND OBJECTIVES: Facial angiofibromas are disfiguring facial lesions, present in up to 80% of patients with tuberous sclerosis complex. Recent elucidation of the complex cell signaling pathways that are disrupted in tuberous sclerosis indicates that rapamycin may be successful in alleviati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koenig, Mary Kay, Hebert, Adelaide A., Roberson, Joan, Samuels, Joshua, Slopis, John, Woerner, Audrey, Northrup, Hope
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2012
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585992/ https://www.ncbi.nlm.nih.gov/pubmed/22934754 http://dx.doi.org/10.2165/11634580-000000000-00000

Ejemplares similares

Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
por: Safa, Gilles
Publicado: (2017)

Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
por: Rauktys, Aubrey, et al.
Publicado: (2008)

Topical rapamycin (sirolimus) for facial angiofibromas
por: Madke, Bhushan
Publicado: (2013)

Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm Trial
por: Slopis, John M., et al.
Publicado: (2018)

Use of Topical Rapamycin in Facial Angiofibromas in Indian Skin Type
por: Viswanath, Vishalakshi, et al.
Publicado: (2016)

Treatment of angiokeratomas of Fordyce with topical rapamycin 0.25% cream
por: Bell, Katheryn A., et al.
Publicado: (2020)

Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2011)

Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
por: Ebrahimi-Fakhari, Daniel, et al.
Publicado: (2017)

Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2013)

Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
por: Lee, Nancy, et al.
Publicado: (2009)

Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis
por: Lin, Yu-Ting, et al.
Publicado: (2022)

Successful Treatment of Non-Langerhans Cell Histiocytosis With Topical Rapamycin in Two Pediatric Cases
por: Effendi, Raden Mohamad Rendy Ariezal, et al.
Publicado: (2022)

Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
por: Govindarajan, Baskaran, et al.
Publicado: (2012)

Two different genetic etiologies for tuberous sclerosis complex (TSC) in a single family
por: Mowrey, Kate, et al.
Publicado: (2020)

Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial
por: Chung, Christina Lee, et al.
Publicado: (2019)

Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
por: Messina, Michael P, et al.
Publicado: (2007)

Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex
por: Sato, Atsushi, et al.
Publicado: (2012)

Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
por: Cabrera-López, Cristina, et al.
Publicado: (2012)

Antiepileptic Effect and Safety Profile of Rapamycin in Pediatric Patients With Tuberous Sclerosis Complex
por: Sadowski, Krzysztof, et al.
Publicado: (2022)

The Efficacy and Safety of Rapamycin in Children with Tuberous Sclerosis: A Cross-sectional Study
por: TEHRANI, Fateme, et al.
Publicado: (2023)

Tuberous Sclerosis Associated with Polycystic Kidney Disease: Effects of Rapamycin after Renal Transplantation
por: Rosado, C., et al.
Publicado: (2013)

Rapamycin-Insensitive Up-Regulation of Adipocyte Phospholipase A2 in Tuberous Sclerosis and Lymphangioleiomyomatosis
por: Li, Chenggang, et al.
Publicado: (2014)

Surviving rapamycin
por: Van Epps, Heather L.
Publicado: (2005)

Rapamycin in mice
por: Swindell, William R.
Publicado: (2017)

Long-Term Exposure and Safety of a Novel Topical Rapamycin Cream for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex: Results From a Single-Center, Open-Label Trial
por: Wheless, Margaret C., et al.
Publicado: (2019)

Topical Apigenin Alleviates Cutaneous Inflammation in Murine Models
por: Man, Mao-Qiang, et al.
Publicado: (2012)

MicroRNA-21 is Induced by Rapamycin in a Model of Tuberous Sclerosis (TSC) and Lymphangioleiomyomatosis (LAM)
por: Trindade, Anil J., et al.
Publicado: (2013)

Insulinoma and Tuberous Sclerosis: A Possible Mechanistic Target of Rapamycin (mTOR) Pathway Abnormality?
por: Kang, Michael Yoon, et al.
Publicado: (2017)

Rapamycin therapy for neonatal tuberous sclerosis complex with cardiac rhabdomyomas: A case report and review
por: Mao, Shanshan, et al.
Publicado: (2017)

Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
por: Lu, Yiyang, et al.
Publicado: (2020)

Safety of inactivated COVID-19 vaccine in tuberous sclerosis complex patients with epilepsy treated with rapamycin
por: Lu, Qian, et al.
Publicado: (2022)

Topical Sirolimus 0.2% Gel for the Management of Tuberous Sclerosis Complex-Related Cutaneous Manifestations: An Interim Analysis of Postmarketing Surveillance in Japan
por: Egami, Akemi, et al.
Publicado: (2023)

Longevity, aging and rapamycin
por: Ehninger, Dan, et al.
Publicado: (2014)

Multifaceted aging and rapamycin
por: Anisimov, Vladimir N.
Publicado: (2013)

Unleashing rapamycin in fibrosis
por: Hillel, Alexander T., et al.
Publicado: (2015)

Rapamycin for the aging skin
por: Blagosklonny, Mikhail V.
Publicado: (2019)

Cancer prevention with rapamycin
por: Blagosklonny, Mikhail V.
Publicado: (2023)

Topical Antibiotic Treatment in Dermatology
por: Dallo, Matthew, et al.
Publicado: (2023)

Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
por: Krueger, Darcy A., et al.
Publicado: (2013)

Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex
por: Ji, Shuang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fi42unsctq8fhfe1i5f434usm0